These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 9796047

  • 1. Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV.
    Fernández IM, Golding H, Benaissa-Trouw BJ, de Vos NM, Harmsen M, Nottet HS, Golding B, Puijk WC, Meloen RH, Snippe H, Kraaijeveld CA.
    Vaccine; 1998 Dec; 16(20):1936-40. PubMed ID: 9796047
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.
    Fernández IM, Snijders A, Benaissa-Trouw BJ, Harmsen M, Snippe H, Kraaijeveld CA.
    J Virol; 1993 Oct; 67(10):5843-8. PubMed ID: 7690411
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
    Sarobe P, Lasarte JJ, Golvano JJ, Prieto I, Gullón A, Soto MJ, Labarga P, Prieto J, Borrás-Cuesta F.
    J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.
    Snijders A, Benaissa-Trouw BJ, Visser-Vernooy HJ, Fernandez I, Snippe H, Kraaijeveld CA.
    Immunology; 1992 Nov; 77(3):322-9. PubMed ID: 1282493
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A vaccine against Semliki Forest virus consisting of a monoclonal anti-idiotypic antibody cross-linked to a protein which contains virus-specific T-helper cell epitopes.
    Kraaijeveld CA, Oosterlaken TA, Snijders A, Benaissa-Trouw BJ, Ekstijn GL, Snippe H.
    Antiviral Res; 1992 Oct 01; 19(4):275-84. PubMed ID: 1281391
    [Abstract] [Full Text] [Related]

  • 10. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 01; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and vaccine efficacy of synthetic peptides containing Semliki Forest virus B and T cell epitopes.
    Snijders A, Benaissa-Trouw BJ, Snippe H, Kraaijeveld CA.
    J Gen Virol; 1992 Sep 01; 73 ( Pt 9)():2267-72. PubMed ID: 1383405
    [Abstract] [Full Text] [Related]

  • 12. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA.
    J Immunol; 1993 Jun 15; 150(12):5647-65. PubMed ID: 8515081
    [Abstract] [Full Text] [Related]

  • 13. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
    Laman JD, Schellekens MM, Lewis GK, Moore JP, Matthews TJ, Langedijk JP, Meloen RH, Boersma WJ, Claassen E.
    AIDS Res Hum Retroviruses; 1993 Jul 15; 9(7):605-12. PubMed ID: 8369165
    [Abstract] [Full Text] [Related]

  • 14. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL, Schad VC, Goodwin WH, Brauer AB, Bollinger BK, Chin RD, Kuo MC.
    J Immunol; 1992 Jun 15; 148(12):3970-7. PubMed ID: 1376346
    [Abstract] [Full Text] [Related]

  • 15. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
    Estaquier J, Boutillon C, Georges B, Ameisen JC, Tartar A, Auriault C.
    J Pept Sci; 1996 Jun 15; 2(3):165-75. PubMed ID: 9231325
    [Abstract] [Full Text] [Related]

  • 16. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 17. A chemically defined synthetic vaccine model for HIV-1.
    Nardelli B, Lu YA, Shiu DR, Delpierre-Defoort C, Profy AT, Tam JP.
    J Immunol; 1992 Feb 01; 148(3):914-20. PubMed ID: 1370524
    [Abstract] [Full Text] [Related]

  • 18. Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection.
    Manca F, De Berardinis P, Fenoglio D, Ombra MN, Li Pira G, Saverino D, Autiero M, Lozzi L, Bracci L, Guardiola J.
    Eur J Immunol; 1996 Oct 01; 26(10):2461-9. PubMed ID: 8898961
    [Abstract] [Full Text] [Related]

  • 19. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
    McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ.
    Vaccine; 1996 Jun 01; 14(8):799-810. PubMed ID: 8817828
    [Abstract] [Full Text] [Related]

  • 20. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Zwart G, van der Hoek L, Valk M, Cornelissen MT, Baan E, Dekker J, Koot M, Kuiken CL, Goudsmit J.
    Virology; 1994 Jun 01; 201(2):285-93. PubMed ID: 7514319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.